Exploiting tumor-associated dendritic cell heterogeneity for novel cancer therapies

Journal of Leukocyte Biology

Volumn 102, Issue 2, 2017, Pages 317-324

  Keirsse, Jiri ^a,b   van Damme, Helena ^a,b   van Ginderachter, Jo A ^a,b   Laoui, Damya ^a,b  

^a GHENT UNIVERSITY   (Belgium)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

DC vaccination; Immunogenic DC; TADC; Tolerogenic DC

Indexed keywords

CANCER IMMUNOTHERAPY; CELL HETEROGENEITY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; MONOCYTE DERIVED DENDRITIC CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TH17 CELL; TH2 CELL; TUMOR ASSOCIATED DENDRITIC CELL; TUMOR IMMUNITY; TUMOR IMMUNOGENICITY; TUMOR MICROENVIRONMENT; ANIMAL; IMMUNOLOGY; NEOPLASM;

ANIMALS; DENDRITIC CELLS; HUMANS; NEOPLASMS;

EID: 85026758189     PISSN: 07415400     EISSN: 19383673     Source Type: Journal    
DOI: 10.1189/jlb.4MR1116-466R     Document Type: Review

References (89)

1. Sharma, P., Allison, J. P. (2015) Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161, 205–214.
2. Steinman, R. M., Banchereau, J. (2007) Taking dendritic cells into medicine. Nature 449, 419–426.
3. Goc, J., Germain, C., Vo-Bourgais, T. K., Lupo, A., Klein, C., Knockaert, S., de Chaisemartin, L., Ouakrim, H., Becht, E., Alifano, M., Validire, P., Remark, R., Hammond, S. A., Cremer, I., Damotte, D., Fridman, W. H., Sautès-Fridman, C., Dieu-Nosjean, M. C. (2014) Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. Cancer Res. 74, 705–715.
4. Fridman, W. H., Galon, J., Pagès, F., Tartour, E., Sautès-Fridman, C., Kroemer, G. (2011) Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res. 71, 5601–5605.
5. Vicari, A. P., Caux, C., Trinchieri, G. (2002) Tumour escape from immune surveillance through dendritic cell inactivation. Semin. Cancer Biol. 12, 33–42.
6. Ma, Y., Shurin, G. V., Gutkin, D. W., Shurin, M. R. (2012) Tumor associated regulatory dendritic cells. Semin. Cancer Biol. 22, 298–306.
7. Bennaceur, K., Chapman, J., Brikci-Nigassa, L., Sanhadji, K., Touraine, J. L., Portoukalian, J. (2008) Dendritic cells dysfunction in tumour environment. Cancer Lett. 272, 186–196.
8. Gentles, A. J., Newman, A. M., Liu, C. L., Bratman, S. V., Feng, W., Kim, D., Nair, V. S., Xu, Y., Khuong, A., Hoang, C. D., Diehn, M., West, R. B., Plevritis, S. K., Alizadeh, A. A. (2015) The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat. Med. 21, 938–945.
9. Movahedi, K., Laoui, D., Gysemans, C., Baeten, M., Stangé, G., Van den Bossche, J., Mack, M., Pipeleers, D., In’t Veld, P., De Baetselier, P., Van Ginderachter, J. A. (2010) Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 70, 5728–5739.
10. Movahedi, K., Guilliams, M., Van den Bossche, J., Van den Bergh, R., Gysemans, C., Beschin, A., De Baetselier, P., Van Ginderachter, J. A. (2008) Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111, 4233–4244.
11. Laoui, D., Keirsse, J., Morias, Y., Van Overmeire, E., Geeraerts, X., Elkrim, Y., Kiss, M., Bolli, E., Lahmar, Q., Sichien, D., Serneels, J., Scott, C. L., Boon, L., De Baetselier, P., Mazzone, M., Guilliams, M., Van Ginderachter, J. A. (2016) The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity. Nat. Commun. 7, 13720.
12. Broz, M. L., Binnewies, M., Boldajipour, B., Nelson, A. E., Pollack, J. L., Erle, D. J., Barczak, A., Rosenblum, M. D., Daud, A., Barber, D. L., Amigorena, S., Van’t Veer, L. J., Sperling, A. I., Wolf, D. M., Krummel, M. F. (2014) Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 26, 638–652.
13. Flies, D. B., Higuchi, T., Harris, J. C., Jha, V., Gimotty, P. A., Adams, S. F. (2016) Immune checkpoint blockade reveals the stimulatory capacity of tumor-associated CD103(+) dendritic cells in late-stage ovarian cancer. OncoImmunology 5, e1185583.
14. Hume, D. A. (2008) Macrophages as APC and the dendritic cell myth. J. Immunol. 181, 5829–5835.
15. Randolph, G., Merad, M. (2013) Reply to: “Can DCs be distinguished from macrophages by molecular signatures?”. Nat. Immunol. 14, 189–190.
16. Gautier, E. L., Shay, T., Miller, J., Greter, M., Jakubzick, C., Ivanov, S., Helft, J., Chow, A., Elpek, K. G., Gordonov, S., Mazloom, A. R., Ma’ayan, A., Chua, W. J., Hansen, T. H., Turley, S. J., Merad, M., Randolph, G. J., Immunological Genome, C.; Immunological Genome Consortium. (2012) Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nat. Immunol. 13, 1118–1128.
17. Miller, J. C., Brown, B. D., Shay, T., Gautier, E. L., Jojic, V., Cohain, A., Pandey, G., Leboeuf, M., Elpek, K. G., Helft, J., Hashimoto, D., Chow, A., Price, J., Greter, M., Bogunovic, M., Bellemare-Pelletier, A., Frenette, P. S., Randolph, G. J., Turley, S. J., Merad, M., Immunological Genome, C.; Immunological Genome Consortium. (2012) Deciphering the transcriptional network of the dendritic cell lineage. Nat. Immunol. 13, 888–899.
18. Broz, M. L., Krummel, M. F. (2015) The emerging understanding of myeloid cells as partners and targets in tumor rejection. Cancer Immunol. Res. 3, 313–319.
19. Durai, V., Murphy, K. M. (2016) Functions of murine dendritic cells. Immunity 45, 719–736.
20. Reizis, B., Bunin, A., Ghosh, H. S., Lewis, K. L., Sisirak, V. (2011) Plasmacytoid dendritic cells: recent progress and open questions. Annu. Rev. Immunol. 29, 163–183.
21. Guilliams, M., Ginhoux, F., Jakubzick, C., Naik, S. H., Onai, N., Schraml, B. U., Segura, E., Tussiwand, R., Yona, S. (2014) Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny. Nat. Rev. Immunol. 14, 571–578.
22. Schlitzer, A., Sivakamasundari, V., Chen, J., Sumatoh, H. R., Schreuder, J., Lum, J., Malleret, B., Zhang, S., Larbi, A., Zolezzi, F., Renia, L., Poidinger, M., Naik, S., Newell, E. W., Robson, P., Ginhoux, F. (2015) Identification of cDC1- and cDC2-committed DC progenitors reveals early lineage priming at the common DC progenitor stage in the bone marrow. Nat. Immunol. 16, 718–728.
23. Mildner, A., Jung, S. (2014) Development and function of dendritic cell subsets. Immunity 40, 642–656.
24. Murphy, T. L., Grajales-Reyes, G. E., Wu, X., Tussiwand, R., Briseño, C. G., Iwata, A., Kretzer, N. M., Durai, V., Murphy, K. M. (2016) Transcriptional control of dendritic cell development. Annu. Rev. Immunol. 34, 93–119.
25. Guilliams, M., Dutertre, C. A., Scott, C. L., McGovern, N., Sichien, D., Chakarov, S., Van Gassen, S., Chen, J., Poidinger, M., De Prijck, S., Tavernier, S. J., Low, I., Irac, S. E., Mattar, C. N., Sumatoh, H. R., Low, G. H., Chung, T. J., Chan, D. K., Tan, K. K., Hon, T. L., Fossum, E., Bogen, B., Choolani, M., Chan, J. K., Larbi, A., Luche, H., Henri, S., Saeys, Y., Newell, E. W., Lambrecht, B. N., Malissen, B., Ginhoux, F. (2016) Unsupervised high-dimensional analysis aligns dendritic cells across tissues and species. Immunity 45, 669–684.
26. Segura, E., Touzot, M., Bohineust, A., Cappuccio, A., Chiocchia, G., Hosmalin, A., Dalod, M., Soumelis, V., Amigorena, S. (2013) Human inflammatory dendritic cells induce Th17 cell differentiation. Immunity 38, 336–348.
27. Conejo-Garcia, J. R., Rutkowski, M. R., Cubillos-Ruiz, J. R. (2016) State-of-the-art of regulatory dendritic cells in cancer. Pharmacol. Ther. 164, 97–104.
28. Kumar, V., Cheng, P., Condamine, T., Mony, S., Languino, L. R., McCaffrey, J. C., Hockstein, N., Guarino, M., Masters, G., Penman, E., Denstman, F., Xu, X., Altieri, D. C., Du, H., Yan, C., Gabrilovich, D. I. (2016) CD45 phosphatase inhibits STAT3 transcription factor activity in myeloid cells and promotes tumor-associated macrophage differentiation. Immunity 44, 303–315.
29. Scarlett, U. K., Rutkowski, M. R., Rauwerdink, A. M., Fields, J., Escovar-Fadul, X., Baird, J., Cubillos-Ruiz, J. R., Jacobs, A. C., Gonzalez, J. L., Weaver, J., Fiering, S., Conejo-Garcia, J. R. (2012) Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J. Exp. Med. 209, 495–506.
30. Hiraoka, N., Yamazaki-Itoh, R., Ino, Y., Mizuguchi, Y., Yamada, T., Hirohashi, S., Kanai, Y. (2011) CXCL17 and ICAM2 are associated with a potential anti-tumor immune response in early intraepithelial stages of human pancreatic carcinogenesis. Gastroenterology 140, 310–321.
31. Chang, W. J., Du, Y., Zhao, X., Ma, L. Y., Cao, G. W. (2014) Inflammation-related factors predicting prognosis of gastric cancer. World J. Gastroenterol. 20, 4586–4596.
32. Harimoto, H., Shimizu, M., Nakagawa, Y., Nakatsuka, K., Wakabayashi, A., Sakamoto, C., Takahashi, H. (2013) Inactivation of tumor-specific CD8 CTLs by tumor-infiltrating tolerogenic dendritic cells. Immunol. Cell Biol. 91, 545–555.
33. Krempski, J., Karyampudi, L., Behrens, M. D., Erskine, C. L., Hartmann, L., Dong, H., Goode, E. L., Kalli, K. R., Knutson, K. L. (2011) Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J. Immunol. 186, 6905–6913.
34. Gabrilovich, D. I., Ostrand-Rosenberg, S., Bronte, V. (2012) Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12, 253–268.
35. Zong, J., Keskinov, A. A., Shurin, G. V., Shurin, M. R. (2016) Tumor-derived factors modulating dendritic cell function. Cancer Immunol. Immunother. 65, 821–833.
36. Flavell, R. A., Sanjabi, S., Wrzesinski, S. H., Licona-Limón, P. (2010) The polarization of immune cells in the tumour environment by TGFbeta. Nat. Rev. Immunol. 10, 554–567.
37. Shurin, G. V., Ouellette, C. E., Shurin, M. R. (2012) Regulatory dendritic cells in the tumor immunoenvironment. Cancer Immunol. Immunother. 61, 223–230.
38. Cubillos-Ruiz, J. R., Silberman, P. C., Rutkowski, M. R., Chopra, S., Perales-Puchalt, A., Song, M., Zhang, S., Bettigole, S. E., Gupta, D., Holcomb, K., Ellenson, L. H., Caputo, T., Lee, A. H., Conejo-Garcia, J. R., Glimcher, L. H. (2015) ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis. Cell 161, 1527–1538.
39. Herber, D. L., Cao, W., Nefedova, Y., Novitskiy, S. V., Nagaraj, S., Tyurin, V. A., Corzo, A., Cho, H. I., Celis, E., Lennox, B., Knight, S. C., Padhya, T., McCaffrey, T. V., McCaffrey, J. C., Antonia, S., Fishman, M., Ferris, R. L., Kagan, V. E., Gabrilovich, D. I. (2010) Lipid accumulation and dendritic cell dysfunction in cancer. Nat. Med. 16, 880–886.
40. Yang, M., Ma, C., Liu, S., Shao, Q., Gao, W., Song, B., Sun, J., Xie, Q., Zhang, Y., Feng, A., Liu, Y., Hu, W., Qu, X. (2010) HIF-dependent induction of adenosine receptor A2b skews human dendritic cells to a Th2-stimulating phenotype under hypoxia. Immunol. Cell Biol. 88, 165–171.
41. Mancino, A., Schioppa, T., Larghi, P., Pasqualini, F., Nebuloni, M., Chen, I. H., Sozzani, S., Austyn, J. M., Mantovani, A., Sica, A. (2008) Divergent effects of hypoxia on dendritic cell functions. Blood 112, 3723–3734.
42. Bakdash, G., Buschow, S. I., Gorris, M. A., Halilovic, A., Hato, S. V., Sköld, A. E., Schreibelt, G., Sittig, S. P., Torensma, R., Duiveman-de Boer, T., Schröder, C., Smits, E. L., Figdor, C. G., de Vries, I. J. (2016) Expansion of a BDCA1+CD14+ myeloid cell population in melanoma patients may attenuate the efficacy of dendritic cell vaccines. Cancer Res. 76, 4332–4346.
43. Norian, L. A., Rodriguez, P. C., O’Mara, L. A., Zabaleta, J., Ochoa, A. C., Cella, M., Allen, P. M. (2009) Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism. Cancer Res. 69, 3086–3094.
44. Mellor, A. L., Munn, D. H. (2004) IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol. 4, 762–774.
45. Pedroza-Gonzalez, A., Zhou, G., Vargas-Mendez, E., Boor, P. P., Mancham, S., Verhoef, C., Polak, W. G., Grünhagen, D., Pan, Q., Janssen, H., Garcia-Romo, G. S., Biermann, K., Tjwa, E. T., IJzermans, J. N., Kwekkeboom, J., Sprengers, D. (2015) Tumor-infiltrating plasmacytoid dendritic cells promote immunosuppression by Tr1 cells in human liver tumors. OncoImmunology 4, e1008355.
46. Aspord, C., Leccia, M. T., Charles, J., Plumas, J. (2013) Plasmacytoid dendritic cells support melanoma progression by promoting Th2 and regulatory immunity through OX40L and ICOSL. Cancer Immunol. Res. 1, 402–415.
47. Ghirelli, C., Reyal, F., Jeanmougin, M., Zollinger, R., Sirven, P., Michea, P., Caux, C., Bendriss-Vermare, N., Donnadieu, M. H., Caly, M., Fourchotte, V., Vincent-Salomon, A., Sigal-Zafrani, B., Sastre-Garau, X., Soumelis, V. (2015) Breast cancer cell-derived GM-CSF licenses regulatory Th2 induction by plasmacytoid predendritic cells in aggressive disease subtypes. Cancer Res. 75, 2775–2787.
48. Wei, S., Kryczek, I., Zou, L., Daniel, B., Cheng, P., Mottram, P., Curiel, T., Lange, A., Zou, W. (2005) Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res. 65, 5020–5026.
49. Stoitzner, P., Green, L. K., Jung, J. Y., Price, K. M., Atarea, H., Kivell, B., Ronchese, F. (2008) Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells. Cancer Immunol. Immunother. 57, 1665–1673.
50. Ilarregui, J. M., Croci, D. O., Bianco, G. A., Toscano, M. A., Salatino, M., Vermeulen, M. E., Geffner, J. R., Rabinovich, G. A. (2009) Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat. Immunol. 10, 981–991.
51. Dalotto-Moreno, T., Croci, D. O., Cerliani, J. P., Martinez-Allo, V. C., Dergan-Dylon, S., Méndez-Huergo, S. P., Stupirski, J. C., Mazal, D., Osinaga, E., Toscano, M. A., Sundblad, V., Rabinovich, G. A., Salatino, M. (2013) Targeting galectin-1 overcomes breast cancer-associated immunosuppression and prevents metastatic disease. Cancer Res. 73, 1107–1117.
52. Hong, Y., Manoharan, I., Suryawanshi, A., Majumdar, T., Angus-Hill, M. L., Koni, P. A., Manicassamy, B., Mellor, A. L., Munn, D. H., Manicassamy, S. (2015) β-Catenin promotes regulatory T-cell responses in tumors by inducing vitamin A metabolism in dendritic cells. Cancer Res. 75, 656–665.
53. Torres-Aguilar, H., Sánchez-Torres, C., Jara, L. J., Blank, M., Shoenfeld, Y. (2010) IL-10/TGF-beta-treated dendritic cells, pulsed with insulin, specifically reduce the response to insulin of CD4+ effector/memory T cells from type 1 diabetic individuals. J. Clin. Immunol. 30, 659–668.
54. Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., David, O., Burow, M., Gordon, A., Dhurandhar, N., Myers, L., Berggren, R., Hemminki, A., Alvarez, R. D., Emilie, D., Curiel, D. T., Chen, L., Zou, W. (2003) Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9, 562–567.
55. Karyampudi, L., Lamichhane, P., Scheid, A. D., Kalli, K. R., Shreeder, B., Krempski, J. W., Behrens, M. D., Knutson, K. L. (2014) Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody. Cancer Res. 74, 2974–2985.
56. Karyampudi, L., Lamichhane, P., Krempski, J., Kalli, K. R., Behrens, M. D., Vargas, D. M., Hartmann, L. C., Janco, J. M., Dong, H., Hedin, K. E., Dietz, A. B., Goode, E. L., Knutson, K. L. (2016) PD-1 blunts the function of ovarian tumor-infiltrating dendritic cells by inactivating NF-kB. Cancer Res. 76, 239–250.
57. Munn, D. H., Mellor, A. L. (2016) IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance. Trends Immunol. 37, 193–207.
58. Han, Y., Chen, Z., Yang, Y., Jiang, Z., Gu, Y., Liu, Y., Lin, C., Pan, Z., Yu, Y., Jiang, M., Zhou, W., Cao, X. (2014) Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma. Hepatology 59, 567–579.
59. Tanoue, S., Kaplan, D. E. (2016) CD14(+) regulatory dendritic cells in patients with hepatocellular carcinoma and cirrhosis. Hepatology 63, 1391–1392.
60. Liu, Q., Zhang, C., Sun, A., Zheng, Y., Wang, L., Cao, X. (2009) Tumor-educated CD11bhighIalow regulatory dendritic cells suppress T cell response through arginase I. J. Immunol. 182, 6207–6216.
61. Kusmartsev, S., Nefedova, Y., Yoder, D., Gabrilovich, D. I. (2004) Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J. Immunol. 172, 989–999.
62. Zhong, K., Song, W., Wang, Q., Wang, C., Liu, X., Chen, D., Zhu, Z., Wu, Y., Zhang, W., Zhang, M. (2012) Murine myeloid dendritic cells that phagocytose apoptotic T cells inhibit the immune response via NO. PLoS One 7, e49378.
63. Si, C., Zhang, R., Wu, T., Lu, G., Hu, Y., Zhang, H., Xu, F., Wei, P., Chen, K., Tang, H., Yeretssian, G., Xiong, H. (2016) Dendritic cell-derived nitric oxide inhibits the differentiation of effector dendritic cells. Oncotarget 7, 74834–74845.
64. Marigo, I., Zilio, S., Desantis, G., Mlecnik, B., Agnellini, A. H., Ugel, S., Sasso, M. S., Qualls, J. E., Kratochvill, F., Zanovello, P., Molon, B., Ries, C. H., Runza, V., Hoves, S., Bilocq, A. M., Bindea, G., Mazza, E. M., Bicciato, S., Galon, J., Murray, P. J., Bronte, V. (2016) T Cell cancer therapy requires CD40-CD40L activation of tumor necrosis factor and inducible nitric-oxide-synthase-producing dendritic cells. Cancer Cell 30, 651.
65. Chiba, S., Baghdadi, M., Akiba, H., Yoshiyama, H., Kinoshita, I., Dosaka-Akita, H., Fujioka, Y., Ohba, Y., Gorman, J. V., Colgan, J. D., Hirashima, M., Uede, T., Takaoka, A., Yagita, H., Jinushi, M. (2012) Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat. Immunol. 13, 832–842.
66. Anderson, A. C. (2012) Tim-3, a negative regulator of anti-tumor immunity. Curr. Opin. Immunol. 24, 213–216.
67. Han, G., Chen, G., Shen, B., Li, Y. (2013) Tim-3: an activation marker and activation limiter of innate immune cells. Front. Immunol. 4, 449.
68. Roberts, E. W., Broz, M. L., Binnewies, M., Headley, M. B., Nelson, A. E., Wolf, D. M., Kaisho, T., Bogunovic, D., Bhardwaj, N., Krummel, M. F. (2016) Critical role for CD103(+)/CD141(+) dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma. Cancer Cell 30, 324–336.
69. Headley, M. B., Bins, A., Nip, A., Roberts, E. W., Looney, M. R., Gerard, A., Krummel, M. F. (2016) Visualization of immediate immune responses to pioneer metastatic cells in the lung. Nature 531, 513–517.
70. Engelhardt, J. J., Boldajipour, B., Beemiller, P., Pandurangi, P., Sorensen, C., Werb, Z., Egeblad, M., Krummel, M. F. (2012) Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells. Cancer Cell 21, 402–417.
71. Salmon, H., Idoyaga, J., Rahman, A., Leboeuf, M., Remark, R., Jordan, S., Casanova-Acebes, M., Khudoynazarova, M., Agudo, J., Tung, N., Chakarov, S., Rivera, C., Hogstad, B., Bosenberg, M., Hashimoto, D., Gnjatic, S., Bhardwaj, N., Palucka, A. K., Brown, B. D., Brody, J., Ginhoux, F., Merad, M. (2016) Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity 44, 924–938.
72. Ruffell, B., Chang-Strachan, D., Chan, V., Rosenbusch, A., Ho, C. M., Pryer, N., Daniel, D., Hwang, E. S., Rugo, H. S., Coussens, L. M. (2014) Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell 26, 623–637.
73. Herbst, R. S., Soria, J. C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., Kohrt, H. E., Horn, L., Lawrence, D. P., Rost, S., Leabman, M., Xiao, Y., Mokatrin, A., Koeppen, H., Hegde, P. S., Mellman, I., Chen, D. S., Hodi, F. S. (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563–567.
74. Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., West, A. N., Carmona, M., Kivork, C., Seja, E., Cherry, G., Gutierrez, A. J., Grogan, T. R., Mateus, C., Tomasic, G., Glaspy, J. A., Emerson, R. O., Robins, H., Pierce, R. H., Elashoff, D. A., Robert, C., Ribas, A. (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571.
75. Sanchez-Paulete, A. R., Labiano, S., Rodriguez-Ruiz, M. E., Azpilikueta, A., Etxeberria, I., Bolaños, E., Lang, V., Rodriguez, M., Aznar, M. A., Jure-Kunkel, M., Melero, I. (2016) Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy. Eur. J. Immunol. 46, 513–522.
76. Laoui, D., Van Overmeire, E., Di Conza, G., Aldeni, C., Keirsse, J., Morias, Y., Movahedi, K., Houbracken, I., Schouppe, E., Elkrim, Y., Karroum, O., Jordan, B., Carmeliet, P., Gysemans, C., De Baetselier, P., Mazzone, M., Van Ginderachter, J. A. (2014) Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population. Cancer Res. 74, 24–30.
77. Van Overmeire, E., Stijlemans, B., Heymann, F., Keirsse, J., Morias, Y., Elkrim, Y., Brys, L., Abels, C., Lahmar, Q., Ergen, C., Vereecke, L., Tacke, F., De Baetselier, P., Van Ginderachter, J. A., Laoui, D. (2016) M-CSF and GM-CSF receptor signaling differentially regulate monocyte maturation and macrophage polarization in the tumor microenvironment. Cancer Res. 76, 35–42.
78. Guéry, L., Dubrot, J., Lippens, C., Brighouse, D., Malinge, P., Irla, M., Pot, C., Reith, W., Waldburger, J. M., Hugues, S. (2014) Ag-presenting CpG-activated pDCs prime Th17 cells that induce tumor regression. Cancer Res. 74, 6430–6440.
79. Markov, O. V., Mironova, N. L., Sennikov, S. V., Vlassov, V. V., Zenkova, M. A. (2015) Prophylactic dendritic cell-based vaccines efficiently inhibit metastases in murine metastatic melanoma. PLoS One 10, e0136911.
80. Di Blasio, S., Wortel, I. M., van Bladel, D. A., de Vries, L. E., Duiveman-de Boer, T., Worah, K., de Haas, N., Buschow, S. I., de Vries, I. J., Figdor, C. G., Hato, S. V. (2016) Human CD1c(+) DCs are critical cellular mediators of immune responses induced by immunogenic cell death. OncoImmunology 5, e1192739.
81. Vacchelli, E., Ma, Y., Baracco, E. E., Sistigu, A., Enot, D. P., Pietrocola, F., Yang, H., Adjemian, S., Chaba, K., Semeraro, M., Signore, M., De Ninno, A., Lucarini, V., Peschiaroli, F., Businaro, L., Gerardino, A., Manic, G., Ulas, T., Günther, P., Schultze, J. L., Kepp, O., Stoll, G., Lefebvre, C., Mulot, C., Castoldi, F., Rusakiewicz, S., Ladoire, S., Apetoh, L., Bravo-San Pedro, J. M., Lucattelli, M., Delarasse, C., Boige, V., Ducreux, M., Delaloge, S., Borg, C., André, F., Schiavoni, G., Vitale, I., Laurent-Puig, P., Mattei, F., Zitvogel, L., Kroemer, G. (2015) Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Science 350, 972–978.
82. Platzer, B., Elpek, K. G., Cremasco, V., Baker, K., Stout, M. M., Schultz, C., Dehlink, E., Shade, K. T., Anthony, R. M., Blumberg, R. S., Turley, S. J., Fiebiger, E. (2015) IgE/FcɛRI-mediated antigen cross-presentation by dendritic cells enhances anti-tumor immune responses. Cell Rep. 10, 1487–1495.
83. Kuhn, S., Yang, J., Ronchese, F. (2015) Monocyte-derived dendritic cells are essential for CD8(+) T cell activation and antitumor responses after local immunotherapy. Front. Immunol. 6, 584.
84. Schreibelt, G., Bol, K. F., Westdorp, H., Wimmers, F., Aarntzen, E. H., Duiveman-de Boer, T., van de Rakt, M. W., Scharenborg, N. M., de Boer, A. J., Pots, J. M., Olde Nordkamp, M. A., van Oorschot, T. G., Tel, J., Winkels, G., Petry, K., Blokx, W. A., van Rossum, M. M., Welzen, M. E., Mus, R. D., Croockewit, S. A., Koornstra, R. H., Jacobs, J. F., Kelderman, S., Blank, C. U., Gerritsen, W. R., Punt, C. J., Figdor, C. G., de Vries, I. J. (2016) Effective clinical responses in metastatic melanoma patients after vaccination with primary myeloid cells. Clin. Cancer Res. 22, 2155–2166.
85. Bloy, N., Pol, J., Aranda, F., Eggermont, A., Cremer, I., Fridman, W. H., Fučíková, J., Galon, J., Tartour, E., Spisek, R., Dhodapkar, M. V., Zitvogel, L., Kroemer, G., Galluzzi, L. (2014) Trial watch: dendritic cell-based anticancer therapy. OncoImmunology 3, e963424.
86. Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., Grunwitz, C., Vormehr, M., Hüsemann, Y., Selmi, A., Kuhn, A. N., Buck, J., Derhovanessian, E., Rae, R., Attig, S., Diekmann, J., Jabulowsky, R. A., Heesch, S., Hassel, J., Langguth, P., Grabbe, S., Huber, C., Türeci, Ö., Sahin, U. (2016) Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 534, 396–401.
87. Dhodapkar, M. V., Sznol, M., Zhao, B., Wang, D., Carvajal, R. D., Keohan, M. L., Chuang, E., Sanborn, R. E., Lutzky, J., Powderly, J., Kluger, H., Tejwani, S., Green, J., Ramakrishna, V., Crocker, A., Vitale, L., Yellin, M., Davis, T., Keler, T. (2014) Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci. Transl. Med. 6, 232ra51.
88. Van Lint, S., Renmans, D., Broos, K., Goethals, L., Maenhout, S., Benteyn, D., Goyvaerts, C., Du Four, S., Van der Jeught, K., Bialkowski, L., Flamand, V., Heirman, C., Thielemans, K., Breckpot, K. (2016) Intratumoral delivery of TriMix mRNA results in T-cell activation by cross-presenting dendritic cells. Cancer Immunol. Res. 4, 146–156.
89. Pitt, J. M., Kroemer, G., Zitvogel, L. (2016) Extracellular vesicles: masters of intercellular communication and potential clinical interventions. J. Clin. Invest. 126, 1139–1143.